文献速递乳腺癌放疗

标准切线放疗野不提供内乳淋巴结 incidental 覆盖

Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes.
PubMed 文献 · Pract Radiat Oncol · 2019-08-05

本研究评估了362例接受切线三维适形放疗的乳腺癌患者内乳淋巴结(IMN)的 incidental 剂量,发现IMN临床靶区平均剂量仅为处方量的36%±28.7%,V40平均为14.2%,且胸骨前脂肪厚度、乳房切除术后放疗、重建手术及锁骨上野均与IMN平均剂量显著相关。结论认为标准切线野在绝大多数病例中不能提供治疗性IMN覆盖。

要点

  • 标准切线野下IMN链平均剂量仅为处方量的36%±28.7%,V40平均14.2%。
  • IMN上、中、下三部分中位剂量分别为7.2%、21.5%、41.7%,差异显著(P<.001)。
  • 若需覆盖IMN,必须进行勾画和仔细的计划审核以确保治疗性覆盖。

核心结论

  • 对于接受标准乳腺/胸壁切线放疗的患者,绝大多数病例中IMN链未获得治疗性 incidental 剂量覆盖。

研究设计与样本

  • 研究纳入2015年1月至2017年7月连续治疗的362例乳腺癌患者,均接受辅助全乳放疗或乳房切除术后放疗(伴或不伴锁骨上±腋窝野),且未有意包含IMN链。
  • IMN临床靶区按RTOG 3509/3510协议勾画并分为上、中、下三等份,计划靶区为临床靶区外放5 mm。
  • 主要终点为IMN计划靶区V40及潜在影响因素,采用线性回归模型分析。

主要发现

  • IMN临床靶区平均剂量为36%±28.7%(标准差)。
  • Kruskal-Wallis检验显示上、中、下三等份中位剂量分别为7.2%、21.5%、41.7%,差异显著(P<.001)。
  • IMN计划靶区平均V40为14.2%(标准差18.7%)。
  • 胸骨前脂肪厚度(回归系数-16.4;P<.001)、乳房切除术后放疗(回归系数24;P<.001)、乳房切除术后重建(回归系数-22.4;P<.001)及增加锁骨上野(回归系数8.8;P=.03)均与IMN平均剂量显著相关。

关键数值与推荐

  • IMN计划靶区V40平均为14.2%(标准差18.7%),即处方剂量40 Gy的覆盖体积百分比。
  • IMN临床靶区平均剂量为36%±28.7%,上、中、下三等份中位剂量分别为7.2%、21.5%、41.7%(P<.001)。

临床怎么用

  • 若区域淋巴结放疗拟包含IMN,需专门勾画IMN并仔细审核计划以确保足够的治疗性覆盖。
  • 标准切线野不应假定可 incidental 覆盖IMN,尤其对于胸骨前脂肪较薄、未行乳房切除术后放疗或重建、未加锁骨上野的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of the study was to evaluate the incidental dose delivered to the internal mammary nodes (IMNs) in patients treated with tangential 3-dimensional conformal radiation therapy and to identify potential parameters that may affect the IMN mean dose. METHODS AND MATERIALS: The study cohort consisted of 362 consecutively treated patients with breast cancer in our center between January 2015 and July 2017 who had received adjuvant whole-breast radiation therapy or postmastectomy radiation with or without a supraclavicular ± axillary field and without intentional inclusion of the IMN chain. The clinical target volume (CTV) for the IMNs was contoured per the Radiation Therapy Oncology Group 3509/3510 protocol and was then divided into 3 subregions: upper, mid, and lower thirds. The planning target volume for the IMNs was generated by adding 5 mm to the CTV. The primary endpoint was to assess the V40 (volume receiving 40 Gy) to the IMN planning target volume and its potential influencing parameters using a linear regression model. RESULTS: The mean (±standard deviation) dose to the CTV IMN chain was 36% ± 28.7%. The Kruskal-Wallis test demonstrated significant differences in the median dose delivered to each level: upper third (7.2%), mid third (21.5%), and lower third (41.7%) (P < .001). The mean V40 IMN planning target volume was 14.2% (standard deviation, 18.7%). Presternal fat thickness (regression coefficient [RC] = -16.4; P < .001), postmastectomy radiation (RC = 24; P < .001), reconstruction after mastectomy (RC = -22.4; P < .001), and the addition of a supraclavicular field (RC = 8.8; P = .03) were all significantly associated with IMN mean dose. CONCLUSIONS: For patients receiving standard breast/chest wall tangential radiation fields, the IMN chain is not incidentally covered with therapeutic doses in the vast majority of cases. Therefore, if regional nodal radiation is intended to include the IMNs, contouring and careful plan review are necessary to ensure adequate therapeutic coverage.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Loganadane G, Kassick M, Kann BH, et al. Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes. Pract Radiat Oncol. 2019. PMID: 31394256. doi:10.1016/j.prro.2019.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。